Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
Obesity has increased to alarming levels in the world. Currently it is estimated that it
occurs in a third of the world's population and it is expected that by 2030, 20% of the
world's adult population will suffer from obesity and 38% will be overweight, and it is
important to highlight that Mexico is among the first in obesity in adults and children.
Obesity leads to the development of diseases such as diabetes mellitus type 2, dyslipidemias,
metabolic syndrome, heart problems, among others.
The treatment for obesity in the first instance are changes in lifestyle, changes in diet and
exercise that have shown, in most patients, have little long-term adherence. There are also
drugs that promote weight loss by modifying the appetite or absorption of macronutrients.
Dapagliflozin plus metformin XR is a medicine composed with an oral antidiabetic of the group
of inhibitors of SGLT2 that has shown to have significant side effects in the weight
reduction and visceral adiposity in people with obesity and in patients with diabetes
mellitus type 2, it is also composed with metformin which also has effects on weight loss in
people with and without type 2 diabetes mellitus.
For these reasons, evaluating this compound drug in people with obesity could provide high
impact information as a complement for the treatment of this condition when compared to the
effects produced by monotherapies.